Abstract:e19161 Background: The phase III ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS), based on which icotinib was approved by State Food and Drug Administration of China. We conducted a safety-monitoring study to assess the safety and efficacy of icotinib in a broad range of patients with advanced non-small-cell lung cancer (NSCLC) across China. Methods: This study was a single-arm, open-label, multi-center trial in advanced NSCLC patients who were suitable for treatment with oral icotinib 125 mg three times daily. Endpoints included safety, objective response rate (ORR) and disease control rate (DCR), were investigated overall and in subgroups. EGFR mutation analysis was performed retrospectively. Results: Between August, 2011 and August, 2012, 6,087 advanced NSCLC patients were registered with a median age of 63 years (range: 21-95 years), and 5,549 patients were evaluable for safety and tumor response. Baseline characteristics (%) were: male/female 50.8/49.2; non-smoker/ex- or current-smoker/no data 67.2/32.7/0.1; adenocarcinoma/non-adenocarcinoma/other 78.6/15.4/6.0; stage IIIB/IV/other 7.4/90.2/2.4; and 1,571(28.3%) patients were ≥ 70 years of age. The overall incidence of drug-related adverse events (AEs) of any grade was 31.5%, in which the most common drug-related AEs including rash (17.4%) and diarrhea (8.5%), and 3 patients experienced with interstitial lung disease (ILD) associated with icotinib. ORR and DCR were 30.0% and 80.6%, respectively. The safety in the elder patients (age ≥70, n=1,571) were similar to that in the overall population, the incidence of drug-related AEs of any grade was 30.6%, most of which were grade I or II. Among 989 patients who undertook EGFR mutation detection, 738 (74.6%) patients were mutation-positive with an ORR of 49.2% and a DCR of 92.3%. Moreover, in 251 (25.4%) wild type patients, the ORR and DCR were 17.8% and 75.7%, respectively. Conclusions: The data from over 6,000 patients was consistent with the results of the ICOGEN study. Icotinib demonstrated efficacy and a favorable toxicity profile in the routine clinical setting.

P3.01-39 Analysis of Acquired EGFR T790M Mutation in Patients with Non-Small Cell Lung Cancer Who Received Icotinib Progress

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.

A Single-Arm, Multicenter, Safety-Monitoring, Phase IV Study of Icotinib in Treating Advanced Non-Small Cell Lung Cancer (NSCLC).

Safety and Efficacy Results of A Phase Iv, Open-Label, Multicenter, Safety-Monitoring Study of Icotinib in Treating Advanced Non-Small Cell Lung Cancer (nsclc): Isafe Study.

Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes

Real‐world Efficacy and Potential Mechanism of Resistance of Icotinib in Asian Advanced Non‐small Cell Lung Cancer with EGFR Uncommon Mutations: A Multi‐center Study

Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China

Icotinib Versus Vinorelbine/platinum As Adjuvant Therapy in Stage II-IIIA Non-Small Cell Lung Cancer with EGFR-mutations: A Multicenter, Randomized, Positive-Controlled, Phase 3, Indication-Expanding Study (EVIDENCE, CCTC-1501).

New EGFR-TKI: a case report of recurrent lung adenocarcinoma successfully treated with icotinib.

Clinical Efficacy of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 18,20 and 21 Uncommon Mutations.

1370Tip Befotertinib Versus Icotinib As First-Line Treatment in Patients with Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer: A Multicenter, Randomized, Open-Label, Controlled Phase III Study

P3.02-027 Lung Adenocarcinoma Patient with EGFR 19 Exon Insert Mutation: I740_K745insIPVAIK and Its Response to Icotinib: A Case Report

P3.01-009 Clinical Efficacy of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 18 E709X Mutations

Efficacy, Safety and Prognostic Factors Analysis of First-Line Icotinib Treatment in Advanced Non-Small Cell Lung Cancer Patients with Mutated EGFR

The Efficacy And Safety Of Icotinib In Patients With Advanced Non-Small Cell Lung Cancer Previously Treated With Chemotherapy: A Single-Arm, Multi-Center, Prospective Study

P2.03-10 Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS

Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis

Final Overall Survival and Updated Biomarker Analysis Results from the Randomized Phase Iii Icogen Trial

A retrospective study of icotinib for the treatment of advanced non-small cell lung adenocarcinoma

An Egfr Extracellular Domain Mutation Data In The East Asian Non-Small Cell Lung Cancer Populations And Response To Icotinib: A Multicenter Study.

Osimertinib for Egfr T790m Positive Non-Small Cell Lung Cancer-Making It Happen, Turning Good Idea into Great Results